
In today’s ACT Brief, we examine why the future of AI in trials is a trusted orchestration system rather than a single model, how coordinators rate eSource-enabled workflows, and what a bipartisan bill proposes for reusable trial networks.
Chiltern has acquired Integrated Development Associates (IDA), a Japanese CRO specializing in integrating Japan and Asia into global drug development.
Chiltern has acquired Integrated Development Associates (IDA), a Japanese CRO specializing in integrating Japan and Asia into global drug development. Under this acquisition, IDA will do business as a subsidiary of Chiltern and be renamed IDA, a Chiltern Company.
Read the full release






